ARA-290 Research Peptide
ARA-290, also called cibinetide, is a chain of eleven amino acids.
Multi-vial Discount Available
Select Size
Research Use Only · Not for human or veterinary consumption.
People also purchased
10mg · $42.00
5mg · $29.00
10mg · $39.00
Certificates of Analysis
Every batch is tested by an independent laboratory before release.
Verify Batch. Lot-level COA, Batch DF/ARA/062026. Check the batch number printed on your vial against the certificate below, which reports the tests run on it.
- Ships Next Day
- Quality Guaranteed
- Cold-Chain Shipping
- Free US Shipping Over $150
What is ARA-290?
ARA-290, also called cibinetide, is a chain of eleven amino acids. It was designed from one face of a single helix inside erythropoietin, the hormone that drives red blood cell production, and it was built to keep that hormone's tissue-protective side while leaving out the blood-making side. The material sold here is made in the laboratory. Research on it has centered on nerve fibers and on pain after nerve injury.
Product information reviewed by Dr. Martina Rossi, PhD
Scientific Contributor and Reviewer · Reviewed
ARA-290 Research & Reference
What ARA-290 does in published studies, and how to work with it in the laboratory, are covered in full on two dedicated pages rather than summarised here, so neither the evidence nor the handling detail is cut short.
Technical Specs
Labeled quantity is net peptide content, not gross salt weight.
ARA-290 Batch Results
Batch DF/ARA/062026
- Laboratory
- Kovera Labs
- Certified
- August 13, 2026
- Sample
- 10 mg vial
- Report
- KVR-2026-D7E5E3
An independent laboratory, Kovera Labs, tested a sample from this batch. These are the results on its certificate.
Purity
Pass99.709%
RP-HPLC, C18 column, 214 nm
Identity
PassConfirmed
LC-MS
Purity is an HPLC figure: the main peak’s share of everything the detector recorded at one wavelength. It’s not a weight. What a purity figure counts →
Check it with the lab. Kovera Labs’ verification page looks a certificate up by its report number. Product, batch, date and results should match this page.
Chromatogram
RP-HPLC · C18 · DAD 214 nm
Frequently Asked Questions
Is ARA-290 third-party tested for purity?+−
Yes. Every batch of ARA-290 is tested by an independent third-party laboratory using HPLC and MS-UPLC, confirming purity and mass identity before the batch is released. Pure Peptides does not test its own material.
Can I see the Certificate of Analysis before buying?+−
Yes. The Certificate of Analysis for the batch currently in stock can be viewed and downloaded directly on this page, before you place an order. Each certificate states the batch number, the measured purity, and the date of analysis, and can be verified independently with the issuing laboratory using the report number it carries.
What does "Research Use Only" mean?+−
It means ARA-290 is supplied for in-vitro laboratory research and for no other purpose, and must not be administered to humans or animals. ARA-290 is legal to purchase in the United States for in vitro and non-clinical laboratory research. It has no FDA approval and no approved human use. ARA-290 is not a scheduled substance under the Controlled Substances Act. Sold strictly for qualified research use, not human or veterinary administration.
How is ARA-290 shipped and stored?+−
ARA-290 ships from US stock with cold-chain packaging and full tracking; orders placed before noon EST on business days are typically dispatched the same business day. On arrival, store the lyophilized powder at -20°C or below, dry and protected from light.
Is ARA-290 the same as cibinetide?+−
Yes. ARA-290, cibinetide and pHBSP are three names for the same eleven-residue peptide, and the published literature is split between them. Searching one name misses a large part of the field.
Has ARA-290 been tested in people?+−
Yes, at phase 2. Three placebo-controlled trials have been published in sarcoidosis-associated small fiber neuropathy. In a 22-patient pilot, a neuropathy symptom score improved against placebo, while pain and fatigue scores improved significantly but equivalently in both arms. A second trial in 38 patients reported improved symptoms and an increase in corneal nerve fibers, with no change in the nerve fiber density measured in skin biopsies. In the largest, a 64-patient phase 2b, only the middle of three doses increased corneal nerve fiber area significantly, and pain improved in every group including placebo. A separate 12-week study in nine patients with diabetic macular edema found no improvement in visual acuity, retinal thickness, retinal sensitivity or tear production, and reported no serious adverse events. Its registry record states it was terminated because the study drug expired. The ARA-290 research article covers these, along with a fourth placebo-controlled trial, in type 2 diabetes with painful neuropathy.
Regeneration Research
Related Compounds
>99%
>99%
>99%
>99%
Reviewed for scientific accuracy
Dr. Martina Rossi, PhD
PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer
Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.